Adaptive Biotechnologies Corporation
ADPTHealthcareNASDAQDiagnostics & Research · Last scanned Oct 24, 2026
Scan Results
Daily timeframeAdaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. At a $4.07B market cap, Adaptive Biotechnologies Corporation ranks as a mid-cap company within healthcare. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.
Market Cap
$4.07B
Beta
2.10
P/E (TTM)
—
P/E (Fwd)
-141.49
EPS (TTM)
$-0.41
EPS (Fwd)
$-0.18
ROE
-38.8%
ROA
-4.1%
Cash
$344.3M
Total Debt
$410.5M
Free CF
$19.0M
52W Change
48.1%
Annual Financials
Cash vs Debt
Where ADPT stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, ADPT finished 19.27% above its 150-day moving average ($20.08) and 24.93% above its 200-day moving average ($19.17). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ADPT overbought or oversold?
At the October 20, 2026 close, ADPT's RSI(14) was 29.0, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, ADPT has $344.3M in cash with $410.5M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Annual free cash flow of $19.0M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at -38.8%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $154.3M (2021) to $277.0M (2025), reflecting a 79% increase over the period.
A beta of 2.10 means ADPT is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Adaptive Biotechnologies Corporation and its sector.